5467-84-5

Basic information

• Product Name: 1,3-bis(2-phenylethyl)urea
• Synonyms: N,N'-bis(2-phenylethyl)urea; urea, N,N'-bis(2-phenylethyl)-
• CAS NO: 5467-84-5
• Molecular Formula: C₁₇H₂₀N₂O
• Molecular Weight: 268.3535
• Mol File: 5467-84-5.mol
• Article Data: 31

Chemical Properties

• Boiling Point: 497.3°C at 760 mmHg
• Flash Point: 186.3°C
• Density: 1.085g/cm³
• Vapor Pressure: 4.99E-10mmHg at 25°C
• Refractive Index: 1.572
• CAS DataBase Reference: 1,3-bis(2-phenylethyl)urea(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3-bis(2-phenylethyl)urea(5467-84-5)
• EPA Substance Registry System: 1,3-bis(2-phenylethyl)urea(5467-84-5)

Safety Data

• Hazardous Substances Data: 5467-84-5(Hazardous Substances Data)

Usage

General Description

1,3-bis(2-phenylethyl)urea, also known as BPEU, is a synthetic chemical compound that belongs to the class of urea derivatives. It is a white crystalline solid with a molecular formula of C18H22N2O and a molecular weight of 282.38 g/mol. BPEU is commonly used as an intermediate in the synthesis of various pharmaceuticals and agrochemicals. It has also been studied for its potential applications in organic synthesis and material science. Additionally, 1,3-bis(2-phenylethyl)urea exhibits low toxicity and is considered to be relatively safe for handling, making it a valuable compound for use in various industrial and research settings.

Upstream product

• 5259-97-2 [1,3]oxazinan-2-one 
• 64-04-0 phenethylamine 
• 1072-70-4 5-methyl-1,3-oxazolidin-2-one 
• 19654-69-4 O-phenethylcarbamoyl-N-(3-phenyl-propionyl)-hydroxylamine 
• 497-18-7 carbonodihydrazide 
• 1943-82-4 phenethyl isocyanate 
• 201230-82-2 carbon monoxide 
• 124-38-9 carbon dioxide 
• 68-12-2 N,N-dimethyl-formamide 
• 92-54-6 4-phenyl-1-piperazine 
• 771-99-3 4-phenylpiperidine 
• 3582-05-6 trifluoromethyl trifluoromethanesulfonate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 67-56-1 methanol 

Downstream Products

• 64-04-0 phenethylamine 
• 1276033-17-0 1,3-diphenethylimidazolidine-2,4,5-trione 
• 496839-76-0 1,3-diphenethylpyrimidine-2,4,6(1H,3H,5H)-trione 
• 1254039-70-7 5-(cyclohexylmethylene)-1,3-diphenethylpyrimidine-2,4,6(1H,3H,5H)-trione 
• 1254039-66-1 5-(2,6-dichlorobenzylidene)-1,3-diphenethylpyrimidine-2,4,6(1H,3H,5H)-trione 
• 1254039-67-2 5-(2-methylbenzylidene)-1,3-diphenethylpyrimidine-2,4,6(1H,3H,5H)-trione 
• 1254038-71-5 6-chloro-1,3-diphenethylpyrimidine-2,4(1H,3H)-dione 
• 1254038-72-6 6-methoxy-1,3-diphenethylpyrimidine-2,4(1H,3H)-dione 

Relevant articles and documents

Oxovanadium(v)-catalyzed amination of carbon dioxide under ambient pressure for the synthesis of ureas

Carbon dioxide is regarded as a reliable C1 building block in organic synthesis because of the nontoxic, abundant, and economical characteristics of carbon dioxide. In this manuscript, a commercially available oxovanadium(v) compound was demonstrated to serve as an efficient catalyst for the catalytic amination of carbon dioxide under ambient pressure in the synthesis of ureas. The catalytic transformation of chiral amines into the corresponding chiral ureas without loss of chirality was also performed. Furthermore, a gram-scale catalytic urea synthesis under ambient pressure was successfully achieved to validate the scalability of this catalytic activation of carbon dioxide. This journal is

Development of a Polo-like Kinase-1 Polo-Box Domain Inhibitor as a Tumor Growth Suppressor in Mice Models

Polo-like kinase-1 (Plk1) plays a key role in mitosis and has been identified as an attractive anticancer drug target. Plk1 consists of two drug-targeting sites, namely, N-terminal kinase domain (KD) and C-terminal polo-box domain (PBD). As KD-targeting inhibitors are associated with severe side effects, here we report on the pyrazole-based Plk1 PBD inhibitor, KBJK557, which showed a remarkable in vitro anticancer effect by inducing Plk1 delocalization, mitotic arrest, and apoptosis in HeLa cells. Further, in vivo optical imaging analysis and antitumorigenic activities in mouse xenograft models demonstrate that KBJK557 preferentially accumulates in cancer cells and selectively inhibits cancer cell proliferation. Pharmacokinetic profiles and partition coefficients suggest that KBJK557 was exposed in the blood and circulated through the organs with an intermediate level of clearance (t1/2, 7.73 h). The present investigation offers a strategy for specifically targeting cancer using a newly identified small-molecule inhibitor that targets the Plk1 PBD.

Base-Mediated Intramolecular Decarboxylative Synthesis of Alkylamines from Alkanoyloxycarbamates

A general and effective method for the synthesis of alkylamine via intramolecular decarboxylation of alkanoyloxycarbamates is described. The alkanoyloxycarbamates are readily prepared with alkyl carboxylic acids and hydroxylamine. The reaction shows a broad range of substrates (primary and secondary alkyl) with functional tolerance, and the corresponding products were obtained in good yields under mild conditions.